middle.news
Cambium Bio Advances Phase 3 with FDA Single-Trial Nod and A$2.4M Placement
9:34am on Tuesday 28th of April, 2026 AEST
•
Healthcare
Read Story
Cambium Bio Advances Phase 3 with FDA Single-Trial Nod and A$2.4M Placement
9:34am on Tuesday 28th of April, 2026 AEST
Key Points
FDA endorses single pivotal Phase 3 trial
ZYBT increases stake to 39.6% via A$2.4M placement
Phase 3 patient enrolment targeted H2 2026
Cash balance stands at A$2.246 million
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Cambium Bio (ASX:CMB)
OPEN ARTICLE